Global Demand for Esoteric Testing in Healthcare

Esoteric Testing Overview

The global esoteric testing market is projected to be USD 56,643 million by 2030 growing at a CAGR of 11.70% during the forecast period. This growth can be ascribed to the growing occurrence of chronic, communicable, and rare hereditary illnesses, and also snowballing the elderly populace.

Furthermore, the elevation of sophisticated technologies, encompassing gene sequencing and gene mass, empowers assured analyses, addressing unmet diagnostic needs with assurance. Additionally, the upswing in the number of tests administered per patient is propelling the progression of the worldwide industry.

On a global scale, the prevalence of chronic conditions, including cancer, diabetes, and heart disease, is progressively widespread. Similarly, the incidence of infectious diseases is escalating at an alarming pace, notably tuberculosis, dengue, HIV, hepatitis B, C, and malaria.

In the recent years, North America had the largest market share, approximately 36%, and the continent is also projected to grow at a strong compound annual growth rate, in the future as well, mainly because of the high disposable income and healthcare spending, the massive populace of the aging and chronic illness patients, and the existence of key businesses in the continent.

Also, Canada is witnessing substantial development in this industry because of its improving healthcare infrastructure, increasing count of government initiatives for making diagnostic facilities available and inexpensive, rising need for ELISA and RT-PCR tests, and the existence of major players offering the related assay kits, reagents, and testing equipment.

Furthermore, the surge in the count of diagnostic tests and technological improvements in esoteric tests are the other main reason supporting the development of the market in the continent.

Read More

North America is Dominating Molecular Quality Controls Market

In 2022, the molecular quality controls market was worth around USD 191.2 million, and it is projected to advance at a 6.4% CAGR from 2022 to 2030, hitting USD 313.7 million in 2030.

This growth can be ascribed to the rising need for external quality assessment provision, the increasing number of qualified clinical labs, the rising government investment for genomics ventures, the snowballing utilization of third-party quality controls, the rising requirement for accurate medicines, the declining price of the sequencing process and hereditary illnesses.

In 2022, the independent controls category led the industry, with the largest revenue share, of approximately 40%, based on product type.

This can be credited to the fact the that they are made independently of reagents, calibrators, and instruments, and tests have the extreme sensitivity rate because of their tremendously unbiased, independent, and sensitivity assessment of a testing system's or technique's performance.

In 2022, North America generated the highest revenue, at approximately 45%. This is because of the high integration of advanced infrastructure, the better number of diagnostic amenities, and the amplified number of authorized clinical labs in the continent.

The second-largest revenue contributor, in the market, is Europe, worldwide. This is mainly because of the snowballing number of cancer research and related biomarkers and the increasing occurrence of cancer.

Hence, the rising need for external quality assessment provision, the increasing number of qualified clinical labs, the rising government investment for genomics ventures, the snowballing utilization of third-party quality controls, the rising requirement for accurate medicines, are the major factors propelling the market.

Read More